EndoPredict is a second generation test – this means it is the newest type of test available for predicting breast cancer recurrence. Second generation tests combine your individual genomic fingerprint with traditional measurements, like tumor size and nodal status, to provide a more accurate assessment of your early and late recurrence risk. Learn more about Read More
Should we use genetic signatures for chemotherapy decisions in ER+/HER2- premenopausal patients? Dr. Anastasia Constantinidou shares key new data from ESMO Congress 2022 demonstrating how EndoPredict can help guide treatment decisions and avoid overtreatment for premenopausal women with ER+, HER2- early breast cancer. Watch Myriad Genetics’ ESMO 2022 Industry Satellite Symposium video below titled, “Controversies Read More
Join Myriad genetics at ESMO 2022 Industry Satellite Symposium on 12 September 2022 from 13:00-14:30 (CEST) for a session on “Controversies in breast and ovarian cancer”. Taking place in Paris Expo Porte de Versailles (France), this year’s symposium will touch on high interest topics such as the use of genetics signatures for chemotherapy decisions and whether HRD tests are interchangeable. Read More
Held on 12 July 2002 (Tuesday) from 3pm – 4pm, the webinar featured Prof. Peter J. Wild, Director of the Dr. Senckenberg Institute of Pathology at University Hospital Frankfurt. He shared about the requirements for core biopsy and surgical sample as well as insightful tips to improve sample quantity and quality. Topics covered during the Read More
International Gynecologic Cancer Society (IGCS) Roundtable Webinar Held on 16 June 2022, the roundtable faculty discussed topics such as the importance of HRD testing, challenges in tumor testing, ways to improve sample quantity and quality as well as the optimal laparoscopic techniques. View the on-demand webinar recording below.